Helix BioPharma Corp achieves last-patient-out in its Phase II trial of topical Interferon Alpha-2b in patients with ano-genital warts.

Helix BioPharma Corp (Helix) has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW). Based on the trial design and schedule, final reporting is expected in mid to late 2010, as previously announced. The double-blind and placebo-controlled Phase II trial was conducted at multiple centres in Germany and Sweden. Patients participating in the trial self-administered active treatment or control cream to the external ano-genital region twice-daily, for five consecutive days/week over a treatment period of eight weeks, with a follow-up visit to assess for lesion recurrence at 16 weeks. Only female subjects were enrolled …